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Background: If literature protocols are followed, conversion of an advanced ketal ester intermediate (available in
kilogram quantities via a published Paal-Knorr synthesis) to cholesterol-lowering drug atorvastatin calcium is hampered
by several process issues, particularly at the final stage where the hemi-calcium salt is obtained.
Results: We developed a high-yielding synthesis of atorvastatin calcium salt on 7 kg scale that affords >99.5% product
purities by introducing the following key improvements: i. isolating the pure product of the ketal deprotection step as
crystalline solid, and ii. using a convenient ethyl acetate extraction procedure to isolate the pure atorvastatin calcium at
the ester hydrolysis and counter-ion exchange step.
Conclusion: The convenient and operationally simple conversion of an advanced intermediate of atorvastatin to the
clinically used hemi-calcium salt form of the drug that is superior to the methods obtainable from the literature is now
available to facilitate the production of atorvastatin calcium on industrial scale.
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Atorvastatin calcium 1 is a known drug originally mar-
keted by Pfizer under the trade name Lipitor (Figure 1) [1].
Atorvastatin inhibits HMG-CoA reductase and blocks the
production of cholesterol in the body which helps control
cholesterol levels in patients at risk of cardiovascular
disease [2]. Following the expiration of the patent life
of Lipitor in 2011 [3], the drug can be produced gene-
rically. This requires the development of efficient,
non-proprietary production processes that would be
available to a wide range of potential producers and
enable the production of this important drug on an
industrial, multi-kilogram scale. The importance of atorva-
statin for public healthcare systems is accentuated, for
example, by the fact that the drug was made part of
the ‘Vital and Essential Drugs List” in the Russian
Federation [4]. As part of a Government-funded initia-
tive to promote local production of the active pharma-
ceutical ingredients for generic drugs, we engaged in
the development of the industry-scale production of
atorvastatin calcium. In this Communication, we* Correspondence: mkrasavin@hotmail.com
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drug that enable its multi-kilogram production.
Results and discussion
There are several known routes to atorvastatin which in-
volve pyrrole ring construction either by [3 + 2] cycloadd-
ition [5], Paal-Knorr condensation [5,6] or the Hantzsch
pyrrole synthesis [7]. The most prominent synthesis,
published over 20 years ago by Brower et al., involves
condensation of the elaborated 1,4-diketone 2 (as a pyr-
role precursor) with fully protected side chain amine 3
(Scheme 1) [8].
This highly convergent route displays a number of
attractive features: i. the high chemical yields (of the key
pyrrole-forming step as well as en route to the synthons
2 and 3), ii. only one step (toward 3) requires substantial
cooling, iii. the synthesis is scalable so as to yield multi-
kilogram quantities of 4, iv. there is no need to perform
tedious and costly chromatographic purification in any
of the steps toward 4. All these features prompted us to
select the route by Brower et al. as the basis for our
kilogram-scale synthesis of atorvastatin calcium. How-
ever, elaboration of intermediate 4 amenable by this
route into the final target material presented several
issues when the published methods were applied. Thehis is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
riginal work is properly credited. The Creative Commons Public Domain










Figure 1 Structure of Atorvastatin calcium.
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the requisite fully deprotected hemi-calcium salt form
involves removal of the ketal protecting group under
acid treatment, ester hydrolysis and counter-ion ex-
change (Scheme 2). Herein we describe a significantly
improved method to convert advanced intermediate 4
into atorvastatin calcium on multi-kilogram scale.
The presence of the two acid-labile protecting groups
in 4 (gem-dimethyl ketal for the diol and tert-butyl ester
for the carboxylic acid) suggests that these two function-
alities could be removed in a single step involving treat-
ment with aqueous HCl, as it was previously reported
[9-11]. However, in our hands, all attempts to bring
about the simultaneous removal of the two protecting
groups led to the formation of a number of unwanted
and difficult-to-separate impurities. This was in accord-
ance with the observations disclosed in an Indian patent
[12] where HPLC analysis reportedly revealed the pres-
ence of at least five major impurities whose ratios
depended on the reaction conditions. Teva Pharmaceuti-
cals reported [13] that the bulk of impurities (e.g., ator-
vastatin lactone [7]) arose in the first step, i.e. the
removal of the ketal protecting group (4→ 5). There-
fore, it has been suggested [14,15] that the diol 5 is puri-
fied and obtained in crystalline form (as opposed to the
oil form obtained by Teva [13]), prior to ester hydrolysis
and hemi-calcium salt formation.
However, when we attempted to follow the published
protocol in methanol [12,13], the quality of the productScheme 1 Preparation of advanced atorvastatin precursor 4 via Paal-5 obtained was below our expectations. Although its 1H
NMR spectrum (see Additional file 1) could be regarded as
adequate, the 2-3 impurities clearly detectable by TLC were
worrisome. However, when the same de-ketalization of 4
with aqueous hydrochloric acid in isopropyl alcohol was
brought about at 60°C, a 96% yield of >99% pure diol 5 was
obtained on simple cooling and filtration. The use of iso-
propyl alcohol, in our view, provided a distinct advantage
of our protocol. It afforded a fine, easy-to-filter solid, while
when we tried the same reaction in aqueous acetonitrile
[14,15], it resulted in a thick and much more difficult-to-
filter precipitate of 5.
Having achieved a clean and high-yielding conversion
of 4 into 5, we proceeded to study the conversion of the
latter into atorvastatin calcium (1). Unfortunately, the
available literature describing this step was somewhat
cryptic about the details. It was clear, however, that the
preparation of 1 could be achieved either by a strong
alkaline solution of sodium hydroxide (in which case
subsequent sodium-to-calcium counter-ion exchange
will be required in a separate step) or directly, using
calcium hydroxide. We found the latter option to be less
convenient due to the low solubility of Ca(OH)2 in water
or organic solvents, which inevitably resulted in the
formation of a biphasic reaction system, longer reac-
tion times and lower conversions. Therefore, we chose
the two-step option for optimizing the process of
converting 4 into 5.
We found that the use of a large excess of sodium
hydroxide in the hydrolysis was detrimental to the
counter-ion swap step where it leads to the formation
and precipitation of Ca(OH)2. A small excess of NaOH
was still required to ensure a sufficient amount of this
hygroscopic reagent was used. We found 1.10-1.15
equiv. of NaOH to be sufficient to achieve full 4 →5
conversions at 40°C in aqueous methanol. In order
to neutralize the excess NaOH careful neutralization
with acid was one option we considered. After some
experimentation, we found that ethyl acetate added
directly to the aqueous alkaline hydrolysis reaction
mixture (in three repeats) not only efficiently quenchedKnorr condensation.
Scheme 2 General route for elaboration of 4 into atorvastatin hemi-calcium.
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drop in pH, Figure 2) it also allowed efficient extraction of
unreacted 4 and other organic impurities possibly present
in the crude reaction mixture, leaving behind an aqueous
solution of atorvastatin sodium salt.
Moreover, we also found that ethyl acetate is useful for
isolating the target compound (1) from the reaction mix-
ture after hydrolysis and cation exchange. Interestingly, 1
has a high solubility in organic solvents while it is only spar-
ingly soluble in water [13]. Therefore, after addition of cal-
cium acetate to the solution of 1 obtained as described
above, the target hemi-calcium salt is formed. The latter
can be efficiently extracted from the aqueous solution,
again, with ethyl acetate. The purity of 1 obtained after
evaporation of the ethyl acetate extracts was over 95% and
it was further improved (to 99.9%) by crystallization of the
product from hot ethanol. The yield of 1 over two steps
was in excess of 78%.
Findings
In summary, we developed a highly efficient method
for converting the advanced key intermediate 4 intoFigure 2 pH of the atorvastatin sodium solution prior to and after repatorvastatin calcium. The key feature of it is the use of
ethyl acetate in the ester hydrolysis – calcium salt
preparation step where the solvent plays three different
roles: i. quenching the excess of NaOH, ii. removing
the unreacted starting material (4) and other potential
organic impurities from the reaction mixture, and iii.
extracting the target compound 1 (as the hemi-calcium
salt) from the aqueous solution. The solvents employed
in these operations (methanol, ethanol and ethyl acet-
ate) are much more environmentally benign compared
to dichloromethane that had been earlier suggested [9]




To a 100 L glass lined reactor isopropyl alcohol (70 L),
water (17.5 L), 4 (7.0 kg, 11.38 mol) and 36% (d =
1.18 g/cm3) hydrochloric acid (0.8 L, 9.3 mol) were
sequentially charged. The resulting suspension was heated,
under vigorous stirring, to 60°C and kept at that tem-
perature for 1 h. The solution was cooled to 5°C andeated extractions with ethyl acetate.
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centrifugation and washed with water (10 L). The resulting
solid was dried at 50°C (0.3 bar) for 18 hours to provide
6.3 kg (96%) of 5.Atorvastatin hemi-calcium salt (1)
Methanol (50 L), water (13 L) and sodium hydroxide
(0.47 kg, 11.78 mol) in 100 L reaction vessel. To this solu-
tion 5 (6.3 kg, 10.25 mol) was added under vigorous stir-
ring. The reaction temperature was raised and maintained
at 40°C for 30 min. The progress of the reaction was moni-
tored by TLC using 50% ethyl acetate in hexanes as eluent.
On completion of the reaction, methanol was distilled from
the reaction vessel at reduced pressure (about 40 L of the
distillate was collected). To the residue, water (30 L) and
ethyl acetate (15 L) were added and the resulting biphasic
mixture was stirred for 30 min. The ethyl acetate layer was
separated and the extraction procedure was repeated twice.
To the resultant aqueous solution, ethyl acetate (30 L) was
added and then calcium acetate monohydrate (1.08 kg,
6.15 mol) of was charged to the stirred biphasic mixture in
one portion. After stirring for 40 min, the layers were sepa-
rated and the bottom layer was discarded. The organic
layer was washed twice with water-methanol mixture
(95:5 v/v) and evaporated under reduced pressure. To the
residue, 96% v/v ethyl alcohol (42 L) was added and the
mixture was refluxed for 1 hour while precipitation was
observed. The resulting suspension was cooled to 20°C
over 3 hours and centrifuged. The product was separated,
washed with 96% v/v ethanol (6 L), dried at 40°C (0.2 bar)
for 12 hours to provide 4.66 kg (78.7% yield) of atorvastatin
hemi-calcium salt of 99.9% purity.Description of additional material
‘Spectral (1H and 13C) NMR characterization data, copies
of the respective spectra for compounds 4, 5 and 1, as well
as a Quality Control (QC) report on a representative batch
of atorvastatin calcium can be found online as Additional
Material for the present article’.Additional file
Additional file 1: NMR spectra of compounds 4, 5, and 1 obtained
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